JP Morgan Chase’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.3K Sell
6,419
-346
-5% -$1.77K ﹤0.01% 6375
2025
Q4
$44.5K Buy
6,765
+5,265
+351% +$33.8K ﹤0.01% 6278
2025
Q3
$10.5K Sell
1,500
-474
-24% -$2.46K ﹤0.01% 6629
2025
Q2
$6.65K Hold
1,974
﹤0.01% 6379
2025
Q1
$3K Hold
1,974
﹤0.01% 6498
2024
Q4
$4.34K Sell
1,974
-450
-19% -$933 ﹤0.01% 6537
2024
Q3
$6.04K Buy
2,424
+450
+23% +$654 ﹤0.01% 6455
2024
Q2
$2.53K Sell
1,974
-7,315
-79% -$12K ﹤0.01% 6497
2024
Q1
$26.8K Sell
9,289
-6,785
-42% -$38K ﹤0.01% 6147
2023
Q4
$118K Sell
16,074
-4,285
-21% -$28.5K ﹤0.01% 5654
2023
Q3
$156K Buy
20,359
+3,577
+21% +$32.9K ﹤0.01% 5216
2023
Q2
$170K Buy
16,782
+15,752
+1,529% +$151K ﹤0.01% 5172
2023
Q1
$10K Buy
1,030
+70
+7% +$397 ﹤0.01% 6118
2022
Q4
$5K Sell
960
-183
-16% -$1.62K ﹤0.01% 6159
2022
Q3
$16K Buy
1,143
+10
+0.9% +$79 ﹤0.01% 5861
2022
Q2
$6K Sell
1,133
-10,836
-91% -$57.8K ﹤0.01% 6122
2022
Q1
$78K Buy
11,969
+6,515
+119% +$62.6K ﹤0.01% 5613
2021
Q4
$88K Buy
5,454
+2,287
+72% +$55.7K ﹤0.01% 5739
2021
Q3
$84K Buy
+3,167
New +$85.1K ﹤0.01% 5653

Other funds holding IMRX

JP Morgan Chase's IMRX Position: Q1 2026 in Review

JP Morgan Chase reduced its Immuneering (IMRX) stake by 5.1% in Q1 2026, selling an estimated $1.77K and leaving 6,419 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6375.

JP Morgan Chase first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $170K in Q2 2023. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • JP Morgan Chase held 6,419 shares of Immuneering worth $31.3K as of Q1 2026.
  • JP Morgan Chase sold 346 Immuneering shares in Q1 2026, an estimated $1.77K.
  • Immuneering made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6375 holding.
  • JP Morgan Chase first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's Immuneering position peaked at $170K in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.